Researchers at Johns Hopkins Medicine have identified human resistin as a critical driver of immune system activation, providing a new mechanism to explain how chronic inflammation is triggered and sustained across conditions like cardiovascular disease and diabetes. According to a study published in PLOS One, the protein acts as a molecular switch that primes and activates macrophages, turning on the powerful NLRP3 inflammasome pathway.
How Human Resistin Triggers the NLRP3 Inflammasome Pathway
Inflammation acts as a natural defense mechanism for the human body, but chronic activation drives tissue damage and disease progression. Until now, the exact triggers for certain inflammatory signals remained unclear. Researchers found that human resistin both prepares and activates macrophages, initiating a cascade of molecular events that results in the release of inflammatory molecules, specifically IL-1β and IL-18.
“By identifying a key molecule that drives inflammatory responses, we’re getting closer to understanding how we might interrupt this process, opening the door to developing more targeted therapies in the future,” said Dr. Roger Anthony Johns, a professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine.
Did you know? The NLRP3 inflammasome plays a central role and has been linked to numerous health conditions, including cardiovascular disease, diabetes and autoimmune disorders.
Implications for Pulmonary Hypertension and Patient Lung Tissue
To confirm laboratory findings translate to actual human pathology, the research team examined lung tissue samples taken from patients suffering from pulmonary hypertension. This serious condition involves high blood pressure in the lungs. Investigators discovered heightened activity of both human resistin and the inflammasome pathway within these patient samples.
“Seeing this heightened activity in patient lung tissue reinforces that this pathway isn’t just something we observe in the lab—it’s directly relevant to human disease,” Dr. Johns stated. This elevated presence suggests the mechanism plays a role in disease severity, positioning resistin as a potential target.
Targeting Resistin for Future Anti-Inflammatory Drug Development
Beyond identifying the pathway, the study demonstrated that blocking human resistin using a targeted antibody successfully reduced the activation of the inflammatory pathway. This intervention points toward a potential new therapeutic strategy.
“This work provides new insight into how inflammation is driven at the cellular level, highlighting the potential for therapies that target resistin to treat a range of inflammatory diseases,” according to Dr. Johns. While additional research is needed, these findings represent an important step toward a better understanding of how inflammation is triggered and sustained in the body.
Frequently Asked Questions
What is human resistin?
Human resistin is a protein identified by researchers as a central driver of immune system activation that acts as a “switch,” both preparing and activating immune cells called macrophages.
How does the NLRP3 inflammasome relate to disease?
The NLRP3 inflammasome is an inflammatory pathway that, when triggered by resistin, releases inflammatory molecules such as IL-1β and IL-18 that can drive tissue damage and disease progression.
Can blocking resistin reduce inflammation?
Yes. The study demonstrated that blocking human resistin with a targeted antibody reduced activation of this inflammatory pathway.
Worth a look